Chase Investment Counsel Corp Buys 11,912 Shares of DaVita Inc. (NYSE:DVA)

Chase Investment Counsel Corp raised its stake in DaVita Inc. (NYSE:DVA - Free Report) by 56.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 33,084 shares of the company's stock after buying an additional 11,912 shares during the period. DaVita comprises about 1.8% of Chase Investment Counsel Corp's portfolio, making the stock its 19th biggest position. Chase Investment Counsel Corp's holdings in DaVita were worth $5,423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Harvard Management Co. Inc. acquired a new position in DaVita in the second quarter valued at $55,115,000. Lazard Asset Management LLC lifted its stake in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after purchasing an additional 153,008 shares during the period. Jupiter Asset Management Ltd. boosted its position in shares of DaVita by 146.7% during the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company's stock valued at $25,840,000 after purchasing an additional 111,311 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in DaVita during the second quarter worth approximately $9,615,000. Finally, International Assets Investment Management LLC bought a new stake in DaVita in the third quarter worth approximately $10,346,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA stock traded down $0.57 during trading on Wednesday, hitting $157.47. The company's stock had a trading volume of 397,208 shares, compared to its average volume of 817,766. The business has a fifty day moving average of $157.34 and a 200-day moving average of $147.23. The company has a market cap of $12.91 billion, a PE ratio of 17.02, a P/E/G ratio of 0.89 and a beta of 0.89. DaVita Inc. has a 52 week low of $89.33 and a 52 week high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.85 earnings per share. As a group, research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company's stock, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the company's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at approximately $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 165,625 shares of company stock valued at $26,238,297 in the last three months. Company insiders own 2.00% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DVA shares. Barclays increased their price target on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. UBS Group raised their target price on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. Finally, TD Cowen increased their target price on DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.